AstraZeneca to buy Fusion Pharma for $2 billion in cash
AstraZeneca will also pay a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4 billion.
RCs have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. (Image credit: Reuters)